All In Biotech

NDA 201367 · Eisai INC

Banzel

Rufinamide · Oral

Orphan

Last checked: Nov 19, 2026Latest source record: May 30, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Mar 3, 2011

Approved uses

2

Original approval plus efficacy supplements

Registered trials

12

6 Phase 3, 0 recruiting

FAERS reports

2,630

1,882 serious, 154 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 15, 2022.

1 I NDICATIONS AND USAGE BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults. BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults ( 1 )

Mechanism: The precise mechanism(s) by which rufinamide exerts its antiepileptic effect is unknown. The results of in vitro studies suggest that the principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Rufinamide (≥ 1 μM) significantly slowed sodium channel recovery from inactivation after a prolonged prepulse in cultured cortical neurons, and limited sustained repetitive firing of sodium-dependent action potentials (EC 50 of 3.8 μM).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BANZEL · RUFINAMIDE 40MG/ML · SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Rufinamide" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure670
  • drug ineffective408
  • off label use256
  • somnolence186
  • diarrhoea120
  • condition aggravated116
  • fatigue111
  • vomiting108
  • drug interaction106
  • multiple-drug resistance102
  • generalised tonic-clonic seizure95
  • decreased appetite91

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20072
20081
200938
201027
201123
201249
201363
201493
2015113
2016130
201797
2018136
2019284
2020237
2021288
2022246
2023161
2024268
2025229
2026145

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Banzel (Rufinamide)

2024 spending

$17.6M

Beneficiaries

480

3,673 claims

Per beneficiary

$36,620

$21.67 per unit

View as table
YearSpending
2020$116,301,070
2021$79,885,763
2022$27,832,595
2023$21,938,164
2024$17,577,531

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 49 on PubMed

Sponsor: Eisai

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.